Sermorelin acetate is the acetate salt of sermorelin, a synthetic 29-amino-acid peptide that reproduces the N-terminal fragment of human growth hormone-releasing hormone (GHRH). It is the shortest portion of native GHRH that retains full receptor activity. In the laboratory it is used as a selective agonist of the GHRH receptor on pituitary somatotroph cells, where researchers study cAMP signalling, growth hormone release and the stability of peptide analogues. This article summarises its structure, mechanism, published research, laboratory applications and the handling requirements that determine data quality.
What is sermorelin acetate?
Sermorelin is GHRH(1-29)-NH2, a linear peptide with an amidated C-terminus. Native human GHRH contains 44 residues, and the first 29 carry the determinants needed to bind and activate the receptor. The sequence is Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. The free peptide has the formula C149H246N44O42S and a molecular weight of approximately 3,358 Da. The acetate salt weighs more than this figure because acetate counter-ions associate with the basic residues, which is why gross vial weight overstates peptide content.
The discovery of GHRH took place in 1982, when groups led by Roger Guillemin and by Jean Rivier and Wylie Vale isolated and sequenced a growth hormone-releasing factor from a human pancreatic tumour associated with acromegaly. The peptide was a 44-residue molecule, and a shorter 40-residue form was identified alongside it. Ling and colleagues later isolated the hypothalamic form and confirmed that it matches the tumour-derived peptide. Structure-activity work then showed that the 1-29 fragment retains the biological potency of the full molecule, and that fragment became the basis of sermorelin.
Sermorelin has been developed and marketed as a pharmaceutical in the past, but the material discussed here is a research reagent. The choice of salt form is a practical matter. Synthetic peptides are usually isolated from reversed-phase HPLC as trifluoroacetate (TFA) salts, and exchanging this for acetate is a common step because residual TFA can interfere with cell-based assays, including proliferation and viability measurements. Researchers who work with primary pituitary cultures often prefer the acetate form for this reason.
Two features of the sequence matter for handling. The unmodified alanine at position 2 is a recognition point for dipeptidyl peptidase-IV (DPP-IV), so the peptide is cleaved rapidly in plasma or serum-containing media. The asparagine at position 8 can deamidate, and the methionine at position 27 is susceptible to oxidation. These liabilities explain why stabilised analogues were later developed from the same backbone.
Mechanism of action
Sermorelin acts at the GHRH receptor (GHRHR), a class B G protein-coupled receptor expressed on anterior pituitary somatotrophs. The mechanism follows the two-domain model typical of this receptor family. The helical C-terminal portion of the peptide engages the receptor’s large extracellular domain, which positions the N-terminal region to interact with the transmembrane core and trigger activation.
Receptor activation couples to the stimulatory G protein Gs, which stimulates adenylyl cyclase and raises intracellular cyclic AMP. Cyclic AMP activates protein kinase A, and PKA phosphorylates CREB, a transcription factor that promotes expression of the growth hormone gene together with the pituitary-specific factor Pit-1. In parallel, PKA-dependent signalling increases calcium entry through voltage-gated channels, which drives exocytosis of stored growth hormone. A laboratory working with sermorelin acetate in pituitary cells can therefore measure the response at several levels, from cAMP accumulation within minutes to hormone release over hours and transcriptional changes over a longer period.
Hormone secretion in the intact axis is governed by a balance between GHRH and somatostatin, the inhibitory hypothalamic peptide. Somatostatin signals through Gi-coupled receptors that lower cAMP and oppose GHRH action, and the interaction between the two is a frequent subject of in-vitro work. GHRH release is pulsatile in vivo, so the short plasma persistence of sermorelin is a feature as well as a limitation, because it produces brief receptor stimulation instead of sustained occupancy. Reported half-lives in pharmacokinetic literature are measured in minutes, and values depend on species and conditions.
The peptide acts upstream of growth hormone itself. It stimulates the pituitary’s own synthesis and release machinery rather than supplying the hormone, so cellular regulatory feedback remains part of any experimental system that includes intact somatotrophs. It does not act at the ghrelin receptor and is distinct in mechanism from the growth hormone releasing peptide family.
What the research shows
The literature on GHRH is extensive, and the studies below were chosen because they define how the molecule is understood.
The first is the original isolation. Guillemin and colleagues, writing in Science in 1982, reported the purification of growth hormone-releasing factor from a human pancreatic tumour that had caused acromegaly in the patient. The work established the existence and primary structure of a peptide that stimulates growth hormone release and resolved a question that had been open since the hypothalamic releasing-factor hypothesis was first proposed. The paper is indexed on PubMed.
The second concerns the hypothalamic peptide. Ling and co-workers reported the isolation, primary structure and synthesis of human hypothalamic somatocrinin, using acid extraction, immunoaffinity chromatography, gel filtration and reversed-phase HPLC on human hypothalamic and pituitary tissue. Their results confirmed that the natural hypothalamic form corresponds to the tumour-derived peptide and supported chemical synthesis as the route to supply. The open-access record is available on PubMed Central.
The third is a molecular biology study. Mayo, Vale, Rivier, Rosenfeld and Evans reported expression-cloning and sequencing of a cDNA encoding human growth hormone-releasing factor in Nature in 1983, which revealed the structure of the precursor from which the mature peptide is processed. This work connected the peptide to its gene and made it possible to study its tissue expression.
The fourth is a transgenic mouse study. Hammer, Brinster, Rosenfeld, Evans and Mayo reported in Nature in 1985 that expression of a human GRF gene in transgenic mice led to increased somatic growth, and related work from the same laboratories described marked pituitary hyperplasia in such animals. These experiments demonstrated in a whole-organism model that sustained GHRH expression drives somatotroph proliferation and growth hormone output. They are cited as descriptions of a research area, and they say nothing about use in people.
Later studies, which are not summarised here study by study, compared GRF analogues in pituitary cell culture, characterised degradation by DPP-IV and designed stabilised derivatives. Researchers should consult the original methods before comparing potency figures across papers, because assay formats differ.
Research applications
The most common use is receptor pharmacology. Cell lines expressing GHRHR, or primary dispersed pituitary cells, are exposed to defined concentrations of the peptide, and responses are quantified by cAMP assay, CREB phosphorylation, reporter-gene output or growth hormone immunoassay of the supernatant. Native-sequence sermorelin gives a reference point against which modified analogues can be ranked for potency and efficacy.
A second area is the study of somatostatin interaction. Co-incubation experiments with somatostatin or its analogues allow researchers to model the opposing arms of the axis in vitro. A third is peptide stability research. Because the native sequence has well-characterised liabilities, namely DPP-IV cleavage, deamidation at position 8 and oxidation at position 27, it serves as a benchmark for evaluating protective substitutions and formulation conditions.
The peptide is also a convenient analytical standard. Its length and defined sequence suit reversed-phase HPLC method development, mass spectrometry, peptide mapping and forced-degradation studies, and it appears in immunoassay validation as a calibrant or cross-reactivity comparator. Finally, structural biologists use the 1-29 fragment as a ligand in studies of class B GPCR binding and activation.
Purity, storage and handling
Analytical verification begins with reversed-phase HPLC, usually monitored at 214 or 220 nm, with purity often specified at 98% or above by peak area. A single chromatogram does not settle identity, so mass spectrometry should confirm the intact mass against the theoretical value near 3,358 Da. Ion-exchange or capillary electrophoresis can add orthogonal evidence. Net peptide content is a distinct measurement, and it matters for quantitative work: the vial contains peptide, acetate counter-ions and bound water, so molar concentrations calculated from gross weight will run high.
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing Sermorelin Acetate should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and researchers weighing up the best peptides supplier uk can apply those same documentation requirements as a consistent benchmark across vendors.
A batch-specific certificate matters because synthesis yield and impurity profile differ from run to run. Deletion sequences, oxidised methionine variants and deamidated species can sit close to the main peak, and only the method conditions and batch number on the certificate show whether the reported purity applies to the vial in hand. A generic specification sheet cannot provide that assurance. The certificate should give the batch number, test date, HPLC conditions, observed mass and counter-ion form.
Lyophilised peptide is best kept at -20°C in a sealed, desiccated container protected from light. Vials should be brought to room temperature before opening so that condensation does not enter the powder. Short periods at ambient temperature during transport are generally tolerated by dry material, but extended warm storage is not advisable. After reconstitution the peptide is far more fragile. Hydrolysis, aggregation, adsorption to plastic and the oxidation and deamidation routes noted above all proceed faster in solution, so reconstituted stock is normally held at 2-8°C for short periods and divided into single-use aliquots to avoid repeated freeze-thaw cycles. Working in low-binding tubes helps limit adsorption losses at low concentrations. Exact stability windows depend on diluent, pH and concentration, so they should be taken from supplier data and checked in-house for critical assays.
Light sensitivity is moderate, since the sequence contains tyrosine and phenylalanine but no tryptophan. Amber vials or dark storage remain good practice, especially for solutions kept for several days.
Frequently asked questions
What is sermorelin acetate used for in the laboratory?
In research settings it is used as a GHRH receptor agonist in pituitary cell and receptor-expressing cell-line assays. Typical applications include cAMP and CREB signalling studies, growth hormone release experiments, comparison with modified analogues and use as an analytical standard for HPLC and mass spectrometry method development.
Is sermorelin the same as GHRH(1-29)?
Yes. Sermorelin is the synthetic form of the first 29 amino acids of human growth hormone-releasing hormone, with an amidated C-terminus. This fragment is the shortest sequence that retains full receptor activity. Analogues such as modified GRF(1-29) differ from it by four amino acid substitutions that improve stability.
How should lyophilised sermorelin be stored?
Lyophilised sermorelin is generally stored at -20°C in a sealed, desiccated container away from light. Vials should reach room temperature before opening. Once reconstituted, solutions are usually kept at 2-8°C for short periods as single-use aliquots, with stability limits confirmed from batch documentation.
What does the acetate in sermorelin acetate mean?
Acetate is the counter-ion that balances the positive charges on the peptide’s basic residues. Many synthetic peptides are isolated as TFA salts, and exchanging to acetate reduces the risk of trifluoroacetate interfering with cell-based assays. The salt form also affects molecular weight and net peptide content calculations.
Sermorelin acetate is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and it must not be administered to people or animals.
